PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-148.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-24.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-23.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-23.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Negative 10Y OCF/share CAGR while TRVN stands at 67.91%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
89.77%
5Y OCF/share CAGR is similar to TRVN's 84.91%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
79.09%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
-5123.81%
Negative 10Y net income/share CAGR while TRVN is at 62.08%. Joel Greenblatt sees a major red flag in long-term profit erosion.
89.73%
5Y net income/share CAGR similar to TRVN's 87.20%. Walter Schloss might see both on parallel mid-term trajectories.
77.51%
3Y net income/share CAGR above 1.5x TRVN's 11.44%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1605.51%
Below 50% of TRVN's 14057.55%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-64.94%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
48.08%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-26.37%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
15.04%
R&D growth drastically higher vs. TRVN's 15.66%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
33.15%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.